Detecting tumor DNA in small automated capillary blood samples from adults with colorectal cancer liver metastases.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational proof-of-concept will enroll 35 adults with progressive colorectal liver metastases to test whether ctDNA can be identified in small automated capillary blood samples. Each participant will provide a capillary sample collected with a TAP® device and a simultaneous venous blood draw as the reference standard. Researchers will compare ctDNA presence and quantitative agreement between capillary and venous samples to determine technical feasibility. Patients on active responsive chemotherapy, those with certain blood‑borne infections or immunodeficiency, or with recent venipuncture‑related skin infections are excluded per protocol.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 21 years
* A history of histologically confirmed (metastatic) colorectal adenocarcinoma
* Currently diagnosed with (progressive) colorectal liver metastases (CRLM)
* Signed informed consent

Exclusion Criteria:

* Patients who are treated and having a response on chemotherapy, as this may have an effect on the investigated biomarker load
* Illiteracy and/or insufficient proficiency of the Dutch language
* Known medical history of superficial or deep skin infection after venipuncture or intravenous line that required antibiotic treatment and or hospital admittance
* Known medical history of immunodeficiency or current use of medical immunosuppressants
* Known medical history of blood-borne diseases such as, but not limited to, the human immunodeficiency virus, hepatitis and viral hemorrhagic fever

Where it's running

• Erasmus MC University Medical Center
  Rotterdam, South Holland, Netherlands Recruiting

Study contacts

• Principal investigator: Cornelis Verhoef, MD, PhD — Erasmus Medical Center
• Study coordinator: Mirthe Ubink, MD
• Email: m.ubink@erasmusmc.nl
• Phone: +31650162308

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Parastomal Hernia After Colorectal Cancer Surgery: Do Radiology Findings Match Quality of Life

  We’re testing how often parastomal hernias appear and change on CT scans after colorectal cancer surgery with a permanent end colostomy, and whether these findings relate to patients’ quality of life.

  Recruiting Region Skane · Malmö, Skåne County · NCT07909148

• ctDNA blood test to spot buried cancer after surgery or treatment in colorectal cancer

  A blood test that looks for specific KRAS mutations in circulating tumor DNA to see if colorectal cancer has left residual disease or is likely to relapse.

  Recruiting Masaryk Memorial Cancer Institute · Brno, Czech Republic · NCT07895459

• Superior hypogastric plexus block to improve recovery after laparoscopic colorectal cancer surgery

  This will test whether adding a superior hypogastric plexus block helps adults having laparoscopic colorectal cancer surgery recover faster and have less pain.

  Recruiting Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07579780

• Comparing virtual reality and in-person art therapy for anxiety, well-being, and sleep in people with colorectal cancer

  This test will see if virtual reality art therapy or in-person art sessions can reduce anxiety and improve psychological well-being and sleep for adults with colorectal cancer receiving outpatient chemotherapy.

  Recruiting Dokuz Eylul University · Izmir, Balçova · NCT07464626

• Secondary Care Pathway Review for Colorectal Cancer

  This study looks at how the colorectal cancer pathway in secondary care is working, using routinely collected data to see how quickly people are diagnosed and treated after a positive FIT test.

  Recruiting University of Edinburgh · Edinburgh and 1 other locations · NCT07430527

• ABT-301 with tislelizumab and bevacizumab for pMMR/non‑MSI‑H advanced or metastatic colorectal cancer

  This trial will test whether adding the oral drug ABT-301 to fixed-dose tislelizumab and bevacizumab is safe and tolerable for adults with pMMR/non‑MSI‑H locally advanced or metastatic colorectal cancer who have had at least two prior systemic therapies.

  Recruiting Phase 1/2 Anbogen Therapeutics, Inc. · Liverpool, New South Wales and 14 other locations · NCT07244705

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.